Genenta Science S.p.A. (GNTA): Price-to-Revenue Ratio

Symbol and logo of brand Genenta Science S.p.A. (GNTA)

Genenta Science S.p.A. is implementing advanced methods for combating solid tumors through macrophage programming. The price-to-sales trend visualizes this potential, where determines the latest valuation metric. Robotic cell cultivation, which eliminates errors, enhances efficiency. However, high R&D costs and the uncertainty of glioblastoma treatment trials create significant financial risks.

GNTA: Genenta Science P/S Multiple 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for Genenta Science S.p.A. (GNTA)

- current price and projected stock value:
Price Chart genenta.com|GNTA - Price Target Chart
- stock exchange capitalization data:
Market Value Genenta|GNTA - Real Price to Acquire Entire Company
- issuer book value statistics:
Accounting Value of a Share Genenta Science|GNTA - Book Capitalization|Market Value to Equity Ratio genenta.com|GNTA - Company Total Assets
- business debt structure and liquidity details:
Debt to Capital Genenta Science S.p.A.|GNTA - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio genenta.com|GNTA - Company Aggregate Debts|Debts to Book Value Genenta|GNTA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Genenta Science|Intermediate Liquidity Ratio genenta.com
- earnings and valuation multiples information:
GNTA - Net Profit|Expected Net Income Genenta Science S.p.A.|GNTA - P/E Multiple|Projected Price to Earnings Ratio genenta.com|GNTA - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Genenta|GNTA - Operating profit EBITDA|Net earnings per share (EPS TTM) Genenta Science|GNTA - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months genenta.com|GNTA - Net earnings per share growth this year|Expected net earnings per share growth next year Genenta Science S.p.A.
- issuer revenue and sales details:
GNTA - Revenue and Sales Volume|Company Sales Forecast genenta.com|GNTA - P/S Multiple|Market Cap to Future Revenue Ratio Genenta
General company analysis:GNTA - Genenta Science SpA
Mass-produced product of Genenta Science SpA

Assessing asset reliability begins by comparing a business's market value with its actual cash flow. The P/S ratio determines how much an investor pays per unit of revenue, reflecting the scale of sales relative to capitalization. For Genenta Science S.p.A. (GNTA), this calculation is critical, as commercial revenues do not yet cover R&D pipeline costs. The dynamics of the P/S market multiple allow for the timely detection of overvalued market expectations against a backdrop of capital burn.

Who Genenta Science S.p.A. competes with

Price-to-Revenue Ratio LEGN (legendbiotech.com)|Price-to-Revenue Ratio Sana Biotechnology, Inc. SANA|Autolus Therapeutics PLC - Price-to-Revenue Ratio|ALLO: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RNAC (Selecta Biosciences Inc.)|CLLS: P/S Multiple|Price-to-Revenue Multiple cariboubio.com CRBU|TIL (Instil Bio) - P/S Multiple|Price to Sales Century Therapeutics Inc IPSC|Price-to-Revenue Ratio Jasper Therapeutics (JSPR)|sentibio.com - Market Cap to Revenue Ratio|P/S Multiple ADAP (Adaptimmune Therapeutics)|CERo Therapeutics Holdings, Inc. (CERO) - Price to Sales|TCRT: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACHL (Achilles Therapeutics)|CRGX (Cargo Therapeutics) - Market Cap to Revenue|PSTX: Market Cap to Sales Volume|TSVT (2seventy bio, Inc.) - P/S Multiple|GRCL: Market Capitalization-to-Revenue Ratio